Chemed [CHE] vs Ensign Group [ENSG] Detailed Stock Comparison
Chemed
NYSE
Loading...
Ensign Group
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemed wins in 14 metrics, Ensign Group wins in 6 metrics, with 0 ties. Chemed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemed | Ensign Group | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 23.36 | 30.66 | Chemed |
| Price-to-Book Ratio | 5.50 | 4.80 | Ensign Group |
| Debt-to-Equity Ratio | 12.15 | 100.93 | Chemed |
| PEG Ratio | -1.00 | 1.76 | Chemed |
| EV/EBITDA | 14.94 | 23.09 | Chemed |
| Profit Margin (TTM) | 11.56% | 7.00% | Chemed |
| Operating Margin (TTM) | 11.00% | 8.46% | Chemed |
| EBITDA Margin (TTM) | 11.00% | 8.46% | Chemed |
| Return on Equity | 24.14% | 17.54% | Chemed |
| Return on Assets (TTM) | 13.56% | 5.30% | Chemed |
| Free Cash Flow (TTM) | $367.97M | $188.95M | Chemed |
| Dividend Yield | 0.18% | 0.20% | Ensign Group |
| 1-Year Return | -19.80% | 16.46% | Ensign Group |
| Price-to-Sales Ratio (TTM) | 2.63 | 2.12 | Ensign Group |
| Enterprise Value | $6.49B | $11.32B | Ensign Group |
| EV/Revenue Ratio | 2.58 | 2.45 | Ensign Group |
| Gross Profit Margin (TTM) | 29.85% | 16.19% | Chemed |
| Revenue per Share (TTM) | $170 | $81 | Chemed |
| Earnings per Share (Diluted) | $19.44 | $5.52 | Chemed |
| Beta (Stock Volatility) | 0.46 | 1.02 | Chemed |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemed vs Ensign Group Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemed | 1.09% | 3.13% | 1.36% | -18.24% | -16.11% | -13.05% |
| Ensign Group | 1.89% | 3.77% | 26.46% | 19.21% | 33.58% | 29.78% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemed | -19.80% | -3.27% | -10.18% | 231.37% | 796.76% | 1,060.10% |
| Ensign Group | 16.46% | 98.37% | 194.07% | 680.98% | 3,775.06% | 4,085.44% |
Performance & Financial Health Analysis: Chemed vs Ensign Group
| Metric | CHE | ENSG |
|---|---|---|
| Market Information | ||
| Market Cap | $6.62B | $9.77B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 148,040 | 366,450 |
| 90 Day Avg. Volume | 169,997 | 451,117 |
| Last Close | $459.05 | $172.44 |
| 52 Week Range | $408.42 - $623.61 | $118.73 - $173.62 |
| % from 52W High | -26.39% | -0.68% |
| All-Time High | $654.62 (Mar 11, 2024) | $173.71 (Aug 22, 2025) |
| % from All-Time High | -29.88% | -0.73% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.19% |
| Quarterly Earnings Growth | -0.26% | 0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.07% |
| Operating Margin (TTM) | 0.11% | 0.08% |
| Return on Equity (TTM) | 0.24% | 0.18% |
| Debt to Equity (MRQ) | 12.15 | 100.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $82.56 | $35.23 |
| Cash per Share (MRQ) | $17.22 | $7.30 |
| Operating Cash Flow (TTM) | $426.78M | $462.89M |
| Levered Free Cash Flow (TTM) | $285.06M | $30.01M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.18% | 0.20% |
| Last 12-Month Dividend | $1.00 | $0.30 |
Valuation & Enterprise Metrics Analysis: Chemed vs Ensign Group
| Metric | CHE | ENSG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 23.36 | 30.66 |
| Forward P/E | 18.24 | 27.56 |
| PEG Ratio | -1.00 | 1.76 |
| Price to Sales (TTM) | 2.63 | 2.12 |
| Price to Book (MRQ) | 5.50 | 4.80 |
| Market Capitalization | ||
| Market Capitalization | $6.62B | $9.77B |
| Enterprise Value | $6.49B | $11.32B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.58 | 2.45 |
| Enterprise to EBITDA | 14.94 | 23.09 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 1.02 |
| Book Value per Share (MRQ) | $82.56 | $35.23 |
Financial Statements Comparison: Chemed vs Ensign Group
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CHE | ENSG |
|---|---|---|
| Revenue/Sales | $646.94M | $1.23B |
| Cost of Goods Sold | $430.53M | $1.03B |
| Gross Profit | $216.41M | $198.79M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $94.76M | $103.90M |
| EBITDA | $112.02M | $140.17M |
| Pre-Tax Income | $95.67M | $112.36M |
| Income Tax | $23.92M | $27.89M |
| Net Income (Profit) | $71.76M | $84.47M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CHE | ENSG |
|---|---|---|
| Cash & Equivalents | $173.88M | $282.67M |
| Total Current Assets | $502.39M | $986.39M |
| Total Current Liabilities | $290.56M | $705.21M |
| Long-Term Debt | $102.08M | $1.91B |
| Total Shareholders Equity | $1.18B | $1.93B |
| Retained Earnings | $2.79B | $1.50B |
| Property, Plant & Equipment | $724.13M | $2.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CHE | ENSG |
|---|---|---|
| Operating Cash Flow | $34.75M | $97.90M |
| Capital Expenditures | $112,000 | $-42.93M |
| Free Cash Flow | $19.46M | $29.29M |
| Debt Repayment | N/A | $-1.01M |
| Common Stock Repurchase | $-33.22M | $-10.79M |
Short Interest & Institutional Ownership Analysis
| Metric | CHE | ENSG |
|---|---|---|
| Shares Short | 384,385 | 1.73M |
| Short Ratio | 1.93 | 3.98 |
| Short % of Float | 0.03% | 0.04% |
| Average Daily Volume (10 Day) | 148,040 | 366,450 |
| Average Daily Volume (90 Day) | 169,997 | 451,117 |
| Shares Outstanding | 14.56M | 57.44M |
| Float Shares | 14.28M | 55.24M |
| % Held by Insiders | 0.02% | 0.03% |
| % Held by Institutions | 0.98% | 0.95% |
Dividend Analysis & Yield Comparison: Chemed vs Ensign Group
| Metric | CHE | ENSG |
|---|---|---|
| Last 12-Month Dividend | $1.00 | $0.30 |
| Last 12-Month Dividend Yield | 0.18% | 0.20% |
| 3-Year Avg Annual Dividend | $1.37 | $0.26 |
| 3-Year Avg Dividend Yield | 0.08% | 0.05% |
| 3-Year Total Dividends | $4.10 | $0.78 |
| Ex-Dividend Date | Nov 18, 2024 | Jun 30, 2025 |